Objective
LV hypertrophy
DIASTOLIC DYSFUNCTION, LV HYPERTROPHY
To determine whether activation of β3ARs by repurposing a β3AR agonist, mirabegron, is safe and effective in preventing progression of LV hypertrophy and diastolic dysfunction among patients with pre- or mild HF.